Former CEO and President of The Revenio Group, Mr. Timo Hildén, has been appointed Nukute’s Chairman of the Board of Directors.
The Finnish medtech start-up renewed its Board to strengthen its strategic competence in dealing with the global medtech market.
Nukute’s Board received a total of three new members. Alongside Hildén, Mr. Tommi Mäkelä as the representative of the Pharmacy Pension Fund (Finland) and Mr. Frans Wuite, CEO of Kompassi Gmbh. Johannes Gullichsen, Pekka Virtanen and Timo Laitinen continue as old members.
"I am honoured and excited to begin my journey with Nukute as the new Chairman of the Board. Nukute demonstrates well the high level of medical technology innovation found in Finland today. The next couple of years will be very interesting as Nukute begins its commercial growth both in Finland and abroad and as it receives more and more clinical interest and acceptance" - Timo Hildén states.
For more information, please contact Chief Marketing Officer Janne Regelin, +35850 3768277, [email protected]
Nukute is a Finnish medtech start-up that develops high-tech tools for the diagnosis and testing of respiratory diseases and conditions. The company's first medically CE marked product innovates home sleep apnea testing (HSAT).